Breaking News

Bristol-Myers Squibb, Imclone Expand Erbitux Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImClone Systems and Bristol-Myers Squibb have amended the terms of their Erbitux agreement regarding the development and promotion in North America. Under this amendment, the companies have expanded the investment in the ongoing clinical development program for Erbitux by as much as several hundred million dollars. BMS will be responsible for development costs up to a threshold value. The companies will share costs beyond this threshold. The companies added Phase II and Phase III trials to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters